Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Vaccination

Prevenar 13 vaccine prevents pneumococcal disease in older adults

Trials show that the 13-valent polysaccharide conjugate vaccine against pneumococcal disease, Pfizer’s Prevenar 13, has demonstrated efficacy in older adults. In the image, a patient is vaccinated

Source: Shutterstock.com

Pfizer’s 13-valent polysaccharide conjugate vaccine Prevenar 13 has demonstrated efficacy against pneumococcal disease in older adults

Pneumococcal polysaccharide conjugate vaccines (in which a bacterial polysaccharide is covalently conjugated to an immunogenic carrier protein) are effective in preventing pneumococcal disease in children.

Now, a 13-valent polysaccharide conjugate vaccine, Pfizer’s Prevenar 13, has demonstrated efficacy in older adults in a study published in The New England Journal of Medicine[1] (2015;372(12):1114–1125). Results of the CAPiTA trial, which involved nearly 85,000 participants aged 65 years and over, show that Prevenar 13 prevented vaccine-type pneumococcal, bacteraemic and nonbacteraemic community-acquired pneumonia (CAP) and vaccine-type invasive pneumococcal disease (IPD).

Pneumococcal CAP and IPD are major causes of morbidity and mortality. The UK’s Joint Committee on Vaccination and Immunisation is currently reviewing the national adult pneumococcal immunisation programme, including the potential inclusion of Prevenar 13.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068227

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.